Literature DB >> 20715106

Tumor infiltration by FcγRIII (CD16)+ myeloid cells is associated with improved survival in patients with colorectal carcinoma.

Giuseppe Sconocchia1, Inti Zlobec, Alessandro Lugli, Diego Calabrese, Giandomenica Iezzi, Eva Karamitopoulou, Efstratios S Patsouris, George Peros, Milo Horcic, Luigi Tornillo, Markus Zuber, Raoul Droeser, Manuele G Muraro, Chantal Mengus, Daniel Oertli, Soldano Ferrone, Luigi Terracciano, Giulio C Spagnoli.   

Abstract

The prognostic significance of macrophage and natural killer (NK) cell infiltration in colorectal carcinoma (CRC) microenvironment is unclear. We investigated the CRC innate inflammatory infiltrate in over 1,600 CRC using two independent tissue microarrays and immunohistochemistry. Survival time was assessed using the Kaplan-Meier method and Cox proportional hazards regression analysis in a multivariable setting. Spearman's rank correlation tested the association between macrophage and lymphocyte infiltration. The Basel study included over 1,400 CRCs. The level of CD16+ cell infiltration correlated with that of CD3+ and CD8+ lymphocytes but not with NK cell infiltration. Patients with high CD16+ cell infiltration (score 2) survived longer than patients with low (score 1) infiltration (p = 0.008), while no survival difference between patients with score 1 or 2 for CD56+ (p = 0.264) or CD57+ cell (p = 0.583) infiltration was detected. CD16+ infiltrate was associated with improved survival even after adjusting for known prognostic factors including pT, pN, grade, vascular invasion, tumor growth and age [(p = 0.001: HR (95% CI) = 0.71 (0.6-0.9)]. These effects were independent from CD8+ lymphocyte infiltration [(p = 0.036: HR (95% CI) = 0.81 (0.7-0.9)] and presence of metastases [(p = 0.002: HR (95% CI) = 0.43 (0.3-0.7)]. Phenotypic studies identified CD16+ as CD45+CD33+CD11b+CD11c+ but CD64- HLA-DR-myeloid cells. Beneficial effects of CD16+ cell infiltration were independently validated by a study carried out at the University of Athens confirming that patients with CD16 score 2 survived longer than patients with score 1 CRCs (p = 0.011). Thus, CD16+ cell infiltration represents a novel favorable prognostic factor in CRC.
Copyright © 2010 UICC.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20715106      PMCID: PMC3426287          DOI: 10.1002/ijc.25609

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  51 in total

Review 1.  Monoclonal antibody therapy of cancer.

Authors:  Gregory P Adams; Louis M Weiner
Journal:  Nat Biotechnol       Date:  2005-09       Impact factor: 54.908

2.  Effector memory T cells, early metastasis, and survival in colorectal cancer.

Authors:  Franck Pagès; Anne Berger; Matthieu Camus; Fatima Sanchez-Cabo; Anne Costes; Robert Molidor; Bernhard Mlecnik; Amos Kirilovsky; Malin Nilsson; Diane Damotte; Tchao Meatchi; Patrick Bruneval; Paul-Henri Cugnenc; Zlatko Trajanoski; Wolf-Herman Fridman; Jérôme Galon
Journal:  N Engl J Med       Date:  2005-12-22       Impact factor: 91.245

Review 3.  Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers.

Authors:  D F Hayes; R C Bast; C E Desch; H Fritsche; N E Kemeny; J M Jessup; G Y Locker; J S Macdonald; R G Mennel; L Norton; P Ravdin; S Taube; R J Winn
Journal:  J Natl Cancer Inst       Date:  1996-10-16       Impact factor: 13.506

4.  Heterogeneity of human blood monocytes: the CD14+ CD16+ subpopulation.

Authors:  H W Ziegler-Heitbrock
Journal:  Immunol Today       Date:  1996-09

Review 5.  Developmental pathways that generate natural-killer-cell diversity in mice and humans.

Authors:  Nicholas D Huntington; Christian A J Vosshenrich; James P Di Santo
Journal:  Nat Rev Immunol       Date:  2007-09       Impact factor: 53.106

6.  Dendritic cells in colorectal cancer correlate with other tumor-infiltrating immune cells.

Authors:  A R Dadabayev; M H Sandel; A G Menon; H Morreau; C J M Melief; R Offringa; S H van der Burg; C Janssen-van Rhijn; N G Ensink; R A E M Tollenaar; C J H van de Velde; P J K Kuppen
Journal:  Cancer Immunol Immunother       Date:  2004-06-17       Impact factor: 6.968

7.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

8.  Production and characterization of monoclonal antibodies against major histocompatibility complex class I chain-related gene A.

Authors:  W Wongsena; G Sconocchia; H S Cho; C-C Chang; X Wang; K Klumkrathok; S Ferrone; C Leelayuwat
Journal:  Tissue Antigens       Date:  2008-11

9.  GM-CSF gene expression and protein production in human colorectal cancer cell lines and clinical tumor specimens.

Authors:  M Trutmann; L Terracciano; C Noppen; J Kloth; M Kaspar; R Peterli; P Tondelli; C Schaeffer; P Zajac; M Heberer; G C Spagnoli
Journal:  Int J Cancer       Date:  1998-07-29       Impact factor: 7.396

10.  Identification and analysis of tumour-associated antigens in hepatocellular carcinoma.

Authors:  Y-Y Shi; H-C Wang; Y-H Yin; W-S Sun; Y Li; C-Q Zhang; Y Wang; S Wang; W-F Chen
Journal:  Br J Cancer       Date:  2005-03-14       Impact factor: 7.640

View more
  50 in total

Review 1.  The secret ally: immunostimulation by anticancer drugs.

Authors:  Lorenzo Galluzzi; Laura Senovilla; Laurence Zitvogel; Guido Kroemer
Journal:  Nat Rev Drug Discov       Date:  2012-02-03       Impact factor: 84.694

2.  HLA class II antigen expression in colorectal carcinoma tumors as a favorable prognostic marker.

Authors:  Giuseppe Sconocchia; Serenella Eppenberger-Castori; Inti Zlobec; Eva Karamitopoulou; Roberto Arriga; Andrea Coppola; Sara Caratelli; Giulio Cesare Spagnoli; Davide Lauro; Alessandro Lugli; Junyi Han; Giandomenica Iezzi; Cristina Ferrone; Amedeo Ferlosio; Luigi Tornillo; Raoul Droeser; Piero Rossi; Antonio Attanasio; Soldano Ferrone; Luigi Terracciano
Journal:  Neoplasia       Date:  2014-01       Impact factor: 5.715

3.  NKp30 isoforms and NKp30 ligands are predictive biomarkers of response to imatinib mesylate in metastatic GIST patients.

Authors:  Sylvie Rusakiewicz; Aurélie Perier; Michaela Semeraro; Jonathan M Pitt; Elke Pogge von Strandmann; Katrin S Reiners; Sandrine Aspeslagh; Christelle Pipéroglou; Frédéric Vély; Alexandre Ivagnes; Sarah Jegou; Niels Halama; Loic Chaigneau; Pierre Validire; Christos Christidis; Thierry Perniceni; Bruno Landi; Anne Berger; Nicolas Isambert; Julien Domont; Sylvie Bonvalot; Philippe Terrier; Julien Adam; Jean-Michel Coindre; Jean-François Emile; Vichnou Poirier-Colame; Kariman Chaba; Benedita Rocha; Anne Caignard; Antoine Toubert; David Enot; Joachim Koch; Aurélien Marabelle; Marion Lambert; Sophie Caillat-Zucman; Serge Leyvraz; Christian Auclair; Eric Vivier; Alexander Eggermont; Christophe Borg; Jean-Yves Blay; Axel Le Cesne; Olivier Mir; Laurence Zitvogel
Journal:  Oncoimmunology       Date:  2016-04-25       Impact factor: 8.110

4.  The Number of Natural Killer Cells in the Largest Diameter Lymph Nodes Is Associated with the Number of Retrieved Lymph Nodes and Lymph Node Size, and Is an Independent Prognostic Factor in Patients with Stage II Colon Cancer.

Authors:  Kazutake Okada; Sotaro Sadahiro; Lin Fung Chan; Takashi Ogimi; Hiroshi Miyakita; Gota Saito; Akira Tanaka; Toshiyuki Suzuki
Journal:  Oncology       Date:  2018-08-23       Impact factor: 2.935

5.  Tumor TP53 expression status, body mass index and prognosis in colorectal cancer.

Authors:  Teppei Morikawa; Aya Kuchiba; Xiaoyun Liao; Yu Imamura; Mai Yamauchi; Zhi Rong Qian; Reiko Nishihara; Kaori Sato; Jeffrey A Meyerhardt; Charles S Fuchs; Shuji Ogino
Journal:  Int J Cancer       Date:  2011-11-19       Impact factor: 7.396

Review 6.  Neutrophils and PMN-MDSC: Their biological role and interaction with stromal cells.

Authors:  Jie Zhou; Yulia Nefedova; Aihua Lei; Dmitry Gabrilovich
Journal:  Semin Immunol       Date:  2017-12-15       Impact factor: 11.130

7.  Cytotoxic Natural Killer Subpopulations as a Prognostic Factor of Malignant Pleural Effusion.

Authors:  Susana Herrera Lara; Estrella Fernández-Fabrellas; Gustavo Juan Samper; Josefa Marco Buades; Rafael Andreu Lapiedra; Amparo Pinilla Moreno; María Morales Suárez-Varela
Journal:  Lung       Date:  2018-12-06       Impact factor: 2.584

Review 8.  Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment.

Authors:  P Allavena; A Mantovani
Journal:  Clin Exp Immunol       Date:  2012-02       Impact factor: 4.330

9.  Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications.

Authors:  Natalia Lapteva; April G Durett; Jiali Sun; Lisa A Rollins; Leslie L Huye; Jian Fang; Varada Dandekar; Zhuyong Mei; Kimberley Jackson; Juan Vera; Jun Ando; Minhtran C Ngo; Elaine Coustan-Smith; Dario Campana; Susann Szmania; Tarun Garg; Amberly Moreno-Bost; Frits Vanrhee; Adrian P Gee; Cliona M Rooney
Journal:  Cytotherapy       Date:  2012-08-17       Impact factor: 5.414

10.  Leukocytes recruited by tumor-derived HMGB1 sustain peritoneal carcinomatosis.

Authors:  Lucia Cottone; Annalisa Capobianco; Chiara Gualteroni; Antonella Monno; Isabella Raccagni; Silvia Valtorta; Tamara Canu; Tiziano Di Tomaso; Angelo Lombardo; Antonio Esposito; Rosa Maria Moresco; Alessandro Del Maschio; Luigi Naldini; Patrizia Rovere-Querini; Marco E Bianchi; Angelo A Manfredi
Journal:  Oncoimmunology       Date:  2016-01-08       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.